

# Lionel Rostaing

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4852059/publications.pdf>

Version: 2024-02-01

129  
papers

6,252  
citations

147566

31  
h-index

71532

76  
g-index

134  
all docs

134  
docs citations

134  
times ranked

5954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. <i>New England Journal of Medicine</i> , 2008, 358, 811-817.	13.9	1,197
2	Belatacept and Long-Term Outcomes in Kidney Transplantation. <i>New England Journal of Medicine</i> , 2016, 374, 333-343.	13.9	593
3	Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. <i>New England Journal of Medicine</i> , 2014, 370, 1111-1120.	13.9	436
4	Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. <i>Kidney International</i> , 2015, 87, 343-349.	2.6	287
5	Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation. <i>Transplantation</i> , 2005, 79, 807-814.	0.5	217
6	Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. <i>Transplantation</i> , 2010, 89, 353-360.	0.5	201
7	TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1995, 59, 1426-1431.	0.5	186
8	Evidence that Clearance of Hepatitis C Virus RNA after $\hat{I}$ -Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2092-2098.	3.0	173
9	Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. <i>Transplantation</i> , 2012, 93, 617-623.	0.5	170
10	Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 430-439.	2.2	158
11	Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate. <i>Annals of Internal Medicine</i> , 2021, 174, 183-191.	2.0	157
12	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	3.0	146
13	Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. <i>Liver Transplantation</i> , 2009, 15, 1262-1269.	1.3	137
14	Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. <i>Transplant International</i> , 2020, 33, 824-825.	0.8	124
15	Natural History of Hepatitis C Virus-Related Liver Fibrosis After Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1704-1712.	2.6	119
16	Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. <i>Transplant International</i> , 2012, 25, 592-602.	0.8	104
17	Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. <i>American Journal of Kidney Diseases</i> , 2003, 42, 184-192.	2.1	83
18	A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. <i>Kidney International</i> , 2014, 86, 1130-1139.	2.6	82

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation. <i>Clinical Pharmacokinetics</i> , 2010, 49, 683-692.	1.6	81
20	Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 20-27.	0.7	78
21	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 648-659.	2.1	78
22	Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 734-740.	1.1	68
23	The safety of calcineurin inhibitors for kidney-transplant patients. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1531-1546.	1.0	66
24	Treatment of Hepatitis C Virus Infection (HCV) After Renal Transplantation: Implications for HCV-Positive Dialysis Patients Awaiting a Kidney Transplant. <i>Transplantation</i> , 2006, 82, 853-856.	0.5	61
25	Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. <i>American Journal of Kidney Diseases</i> , 2005, 45, 193-196.	2.1	55
26	No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. <i>Transplant International</i> , 2010, 23, 594-601.	0.8	54
27	Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. <i>Transplant International</i> , 2012, 25, e62-e66.	0.8	43
28	Conversion from Calcineurin Inhibitor to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3252-3264.	3.0	41
29	Amantadine therapy in renal transplant patients with hepatitis C virus infection. <i>Journal of Clinical Virology</i> , 2004, 30, 110-114.	1.6	39
30	The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival. <i>Transplantation</i> , 2020, 104, 1263-1271.	0.5	39
31	Costimulation Blockade in Kidney Transplantation. <i>Transplantation</i> , 2016, 100, 2315-2323.	0.5	36
32	An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 285-294.	1.0	34
33	Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. <i>Infection, Genetics and Evolution</i> , 2015, 35, 50-55.	1.0	33
34	Belatacept in kidney transplantation and its limitations. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 359-367.	1.3	32
35	Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. <i>Kidney International</i> , 2019, 95, 896-904.	2.6	31
36	Belatacept-versusCyclosporine-Based Immunosuppression in Renal Transplant Recipients with Pre-existing Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2696-2704.	2.2	30

#	ARTICLE	IF	CITATIONS
37	The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. <i>Kidney International</i> , 2018, 94, 616-624.	2.6	28
38	Place of mTOR inhibitors in management of BKV infection after kidney transplantation. <i>Journal of Nephropathology</i> , 2016, 5, 1-7.	0.1	26
39	once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important <i>de novo</i> and stable kidney transplant recipient subgroups. <i>Transplant International</i> , 2016, 29, 603-611.	0.8	25
40	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.	3.0	23
41	Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. <i>Transplant International</i> , 2015, 28, 255-258.	0.8	22
42	Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept. <i>Transplantation</i> , 2021, 105, e259-e260.	0.5	22
43	Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viremia and/or viremia. <i>Transplant International</i> , 2016, 29, 315-322.	0.8	21
44	Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates. <i>American Journal of Transplantation</i> , 2022, 22, 71-84.	2.6	20
45	Tailoring tacrolimus therapy in kidney transplantation. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 581-588.	1.3	19
46	ADHERE: randomized controlled trial comparing renal function in <i>de novo</i> kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. <i>Transplant International</i> , 2017, 30, 83-95.	0.8	18
47	Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2020, 9, 3479.	1.0	17
48	Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. <i>Transplantation Reviews</i> , 2020, 34, 100531.	1.2	17
49	Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1316.	1.0	16
50	Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates. <i>Transplantation Direct</i> , 2021, 7, e690.	0.8	16
51	Treatment of large plasma volumes using specific immunoadsorption to desensitize ABO-incompatible kidney-transplant candidates. <i>Journal of Nephropathology</i> , 2016, 5, 90-97.	0.1	16
52	Adverse effects of immunosuppression after liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 54-55, 101762.	1.0	15
53	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1961-1969.	0.4	13
54	Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. <i>Journal of Nephropathology</i> , 2015, 4, 110-5.	0.1	13

#	ARTICLE	IF	CITATIONS
55	Immunoabsorption and Hemodialysis as a Tandem Procedure: A Single-Center Experience of More than 60 Procedures. <i>International Journal of Artificial Organs</i> , 2015, 38, 304-310.	0.7	12
56	Should kidney allografts from old donors be allocated only to old recipients?. <i>Transplant International</i> , 2020, 33, 849-857.	0.8	12
57	Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled?. <i>Reviews in Medical Virology</i> , 2021, 31, 1-9.	3.9	12
58	Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response. <i>Journal of Clinical Medicine</i> , 2021, 10, 5159.	1.0	12
59	Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1257-1265.	0.8	11
60	Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol. <i>Transplant Immunology</i> , 2019, 56, 101207.	0.6	11
61	Prospects for improved glomerular filtration rate estimation based on creatinine results from a transnational multicentre study. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 674-683.	1.4	11
62	Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.	0.4	11
63	Hepatitis C virus infection in nephrology patients. <i>Journal of Nephropathology</i> , 2013, 2, 217-33.	0.1	11
64	Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring. <i>Frontiers in Medicine</i> , 2021, 8, 790547.	1.2	11
65	Successful Transplantation in ABO and HLA Incompatible Living Kidney Transplant Patients: A Report on 12 Cases. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 507-516.	0.4	10
66	Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4359.	1.0	10
67	Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant. <i>Experimental and Clinical Transplantation</i> , 2014, 12, 212-9.	0.2	10
68	A prospective study in male recipients of kidney transplantation reveals divergent patterns for inhibin B and testosterone secretions. <i>Basic and Clinical Andrology</i> , 2014, 24, 11.	0.8	9
69	New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 845-855.	1.0	9
70	Renal complications of liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1135-1142.	1.4	9
71	Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models. <i>Blood Purification</i> , 2018, 46, 239-245.	0.9	9
72	Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?. <i>EBioMedicine</i> , 2018, 34, 2-3.	2.7	9

#	ARTICLE	IF	CITATIONS
73	Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 703-711.	0.4	9
74	Immortal Time-Biasâ€“Corrected Survival of Highly Sensitized Patients and HLA-desensitized Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2629-2638.	0.4	9
75	Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters. <i>Transplantation Direct</i> , 2020, 6, e517.	0.8	9
76	Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review. <i>Frontiers in Immunology</i> , 2022, 13, 839380.	2.2	9
77	Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate. <i>Case Reports in Transplantation</i> , 2014, 2014, 1-4.	0.1	8
78	Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. <i>Journal of Hepatology</i> , 2014, 61, 963-965.	1.8	8
79	Outcomes at 7Âyears postâ€transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in <scp>BENEFIT</scp> and <scp>BENEFIT</scp>â€<scp>EXT</scp>. <i>Clinical Transplantation</i> , 2018, 32, e13225.	0.8	8
80	Immunoabsorption for Recurrent Primary Focal Segmental Glomerulosclerosis on Kidney Allografts: A Single-Center Experience and Literature Review. <i>Blood Purification</i> , 2020, 49, 322-333.	0.9	8
81	An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.	0.3	7
82	pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 55-66.	1.3	7
83	Early post-transplant complications following ABO-incompatible kidney transplantation. <i>Journal of Nephrology</i> , 2016, 5, 19-27.	0.1	7
84	Age-adapted percentiles of measured glomerular filtration in healthy individuals: extrapolation to living kidney donors over 65Âyears. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 401-407.	1.4	7
85	Do kidney histology lesions predict longâ€term kidney function after liver transplantation?. <i>Clinical Transplantation</i> , 2012, 26, 927-934.	0.8	6
86	Novel approaches to improve recipient and allograft outcomes. <i>Nature Reviews Nephrology</i> , 2017, 13, 73-74.	4.1	6
87	Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, singleâ€membrane filtration, and doubleâ€filtration plasmapheresis. <i>Journal of Clinical Apheresis</i> , 2021, 36, 408-419.	0.7	6
88	Desensitization in the Setting of HLA-Incompatible Kidney Transplant. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 367-375.	0.2	6
89	Isolated Aspergillosis Myocardial Abscesses in a Liver-Transplant Patient. <i>Case Reports in Transplantation</i> , 2014, 2014, 1-3.	0.1	5
90	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. <i>Journal of Transplantation</i> , 2015, 2015, 1-5.	0.3	5

#	ARTICLE	IF	CITATIONS
91	Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. <i>International Urology and Nephrology</i> , 2019, 51, 1639-1647.	0.6	5
92	High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. <i>International Urology and Nephrology</i> , 2019, 51, 2243-2254.	0.6	5
93	Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. <i>International Urology and Nephrology</i> , 2019, 51, 2295-2304.	0.6	5
94	Effects of immunoadsorption combined with membrane filtration on complement markers " results of a randomized, controlled, crossover study. <i>Transplant International</i> , 2019, 32, 876-883.	0.8	5
95	The Mayo Adhesive Probability score can help predict intra- and postoperative complications in patients undergoing laparoscopic donor nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 2775-2781.	1.2	5
96	Effect of immunoadsorption alone or combined with membrane filtration on hemostasis parameters. <i>Journal of Clinical Apheresis</i> , 2020, 35, 444-452.	0.7	5
97	Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review. <i>Journal of Clinical Apheresis</i> , 2021, 36, 348-363.	0.7	5
98	The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease. <i>International Urology and Nephrology</i> , 2021, 53, 749-761.	0.6	5
99	Protocol Biopsies on de novo Renal-Transplants at 3 Months after Surgery: Impact on 5-Year Transplant Survival. <i>Journal of Clinical Medicine</i> , 2021, 10, 3635.	1.0	5
100	Epidemiology of chronic kidney diseases in the Republic of Guinea; future dialysis needs. <i>Journal of Nephropathology</i> , 2015, 4, 127-33.	0.1	5
101	Costimulation Blockade in Kidney Transplantation. <i>Transplantation</i> , 2016, 100, 2516-2518.	0.5	4
102	Hemodialysis coupled with rheopheresis in calciphylaxis: A winning combination. <i>Journal of Clinical Apheresis</i> , 2019, 34, 631-633.	0.7	4
103	Isoagglutinin removal by plasma centrifugation or filtration (single or double): A prospective study in a single center. <i>Journal of Clinical Apheresis</i> , 2021, 36, 149-160.	0.7	4
104	Fibrinogen reconstitution after therapeutic apheresis: Comparison of double-filtration plasmapheresis, plasma exchange, and immunoadsorption. <i>Journal of Clinical Apheresis</i> , 2021, 36, 574-583.	0.7	4
105	Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review. <i>Therapeutic Apheresis and Dialysis</i> , 2023, 27, 159-169.	0.4	4
106	Advagraf® with or without an induction therapy for <i>de novo</i> kidney-transplant recipients. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 461-467.	1.3	3
107	Early Prediction of Graft Outcomes After Kidney Transplantation From Donors After Circulatory Death: Biomarkers and Transplantation Characteristics. <i>Transplantation Proceedings</i> , 2019, 51, 3234-3243.	0.3	3
108	Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. <i>Transplantation Proceedings</i> , 2020, 52, 3179-3185.	0.3	3



#	ARTICLE	IF	CITATIONS
109	Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation. <i>Journal of Clinical Apheresis</i> , 2021, 36, 584-594.	0.7	3
110	Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.	0.8	3
111	What are the Management Issues for Hepatitis C in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 451-455.	0.7	2
112	An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient. <i>Case Reports in Transplantation</i> , 2019, 2019, 1-3.	0.1	2
113	Predonation Single Kidney Glomerular Filtration Rate in Living Kidney Transplantation to Predict Graft Function and Donor Functional Gain. <i>Transplantation Proceedings</i> , 2020, 52, 712-721.	0.3	2
114	Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies. <i>Case Reports in Oncology</i> , 2021, 14, 676-680.	0.3	2
115	Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates. <i>Experimental and Clinical Transplantation</i> , 2015, 13 Suppl 1, 201-6.	0.2	2
116	Very Early Severe Posttransplant Recurrent Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Kidney Transplantation: Two Case Reports. <i>Case Reports in Nephrology</i> , 2022, 2022, 1-5.	0.2	2
117	Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization. <i>Journal of Clinical Medicine</i> , 2022, 11, 91.	1.0	2
118	Genomic Mutations of BK Polyomavirus in Patients after Kidney Transplantation: A Cross-Sectional Study in Vietnam. <i>Journal of Clinical Medicine</i> , 2022, 11, 2544.	1.0	2
119	Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series. <i>Case Reports in Nephrology</i> , 2019, 2019, 1-4.	0.2	1
120	Where do we stand in 2020 regarding induction therapy after kidney transplantation?. <i>Transplant International</i> , 2020, 33, 858-862.	0.8	1
121	Baseline anti-CMV cellular immunity is similar between patients with a kidney transplant or receiving hemodialysis. <i>Transplant International</i> , 2020, 33, 961-962.	0.8	1
122	Impact of Immunosuppressive Strategies on Post-Kidney Transplantation Thrombocytopenia. <i>Transplantation Proceedings</i> , 2021, 53, 941-949.	0.3	1
123	Success of rheopheresis to treat digital hypoperfusion ischemic syndrome. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 362-364.	0.4	1
124	Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis. <i>International Urology and Nephrology</i> , 2021, 53, 591-600.	0.6	1
125	A Case of <b><i>Pneumocystis jirovecii</i></b> Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection. <i>Case Reports in Nephrology and Dialysis</i> , 2021, 11, 10-15.	0.3	1
126	How to improve clotting factors depletion in double-filtration plasmapheresis. <i>Journal of Clinical Apheresis</i> , 2021, 36, 766-774.	0.7	1



#	ARTICLE	IF	CITATIONS
127	Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. , 2020, 33, 824.		1
128	Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review. Journal of Clinical Medicine, 2022, 11, 93.	1.0	1
129	Early Steroid Withdrawal After Kidney Transplantation in Patients at Risk for New-Onset Diabetes After Transplantation. Transplantation Proceedings, 2021, 53, 2216-2226.	0.3	0